WallStreetZenWallStreetZen

NASDAQ: CLRB
Cellectar Biosciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CLRB

Based on 1 analyst offering 12 month price targets for Cellectar Biosciences Inc

Min Forecast
$10.00+290.78%
Avg Forecast
$10.00+290.78%
Max Forecast
$10.00+290.78%

Should I buy or sell CLRB stock?

Based on 1 analyst offering ratings for Cellectar Biosciences Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CLRB stock forecasts and price targets.

CLRB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-10

1 of 1

Forecast return on equity

Is CLRB forecast to generate an efficient return?

Company
69.57%
Industry
64.47%
Market
171.75%
CLRB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CLRB forecast to generate an efficient return on assets?

Company
39.65%
Industry
30.51%
CLRB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CLRB earnings per share forecast

What is CLRB's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$3.75
Avg 2 year Forecast
-$3.14
Avg 3 year Forecast
-$0.93

CLRB revenue forecast

What is CLRB's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$14.7M
Avg 3 year Forecast
$47.2M

CLRB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CLRB$2.56$10.00+290.78%Strong Buy
CMMB$1.46N/AN/A
CDT$2.25N/AN/A
RVPH$0.87$38.20+4,306.00%Strong Buy
IMNN$2.68$10.00+273.13%Strong Buy
View Top Biotech Stocks

Cellectar Biosciences Stock Forecast FAQ

Is Cellectar Biosciences Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: CLRB) stock is to Strong Buy CLRB stock.

Out of 1 analyst, 1 (100%) are recommending CLRB as a Strong Buy, 0 (0%) are recommending CLRB as a Buy, 0 (0%) are recommending CLRB as a Hold, 0 (0%) are recommending CLRB as a Sell, and 0 (0%) are recommending CLRB as a Strong Sell.

If you're new to stock investing, here's how to buy Cellectar Biosciences stock.

What is CLRB's earnings growth forecast for 2026-2028?

(NASDAQ: CLRB) Cellectar Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.3%.

Cellectar Biosciences's earnings in 2026 is -$21,791,037.On average, 5 Wall Street analysts forecast CLRB's earnings for 2026 to be -$15,886,915, with the lowest CLRB earnings forecast at -$22,480,316, and the highest CLRB earnings forecast at -$12,287,894. On average, 5 Wall Street analysts forecast CLRB's earnings for 2027 to be -$13,306,373, with the lowest CLRB earnings forecast at -$22,023,230, and the highest CLRB earnings forecast at -$6,722,725.

In 2028, CLRB is forecast to generate -$3,950,104 in earnings, with the lowest earnings forecast at -$5,942,117 and the highest earnings forecast at -$2,537,717.

What is CLRB's revenue growth forecast for 2026-2028?

(NASDAQ: CLRB) Cellectar Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.06%.

Cellectar Biosciences's revenue in 2026 is $0.On average, 5 Wall Street analysts forecast CLRB's revenue for 2026 to be $0, with the lowest CLRB revenue forecast at $0, and the highest CLRB revenue forecast at $0. On average, 5 Wall Street analysts forecast CLRB's revenue for 2027 to be $62,228,133, with the lowest CLRB revenue forecast at $35,243,952, and the highest CLRB revenue forecast at $90,357,149.

In 2028, CLRB is forecast to generate $200,146,809 in revenue, with the lowest revenue forecast at $88,817,982 and the highest revenue forecast at $329,000,089.

What is CLRB's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: CLRB) forecast ROA is 39.65%, which is higher than the forecast US Biotechnology industry average of 30.51%.

What is CLRB's Price Target?

According to 1 Wall Street analyst that have issued a 1 year CLRB price target, the average CLRB price target is $10.00, with the highest CLRB stock price forecast at $10.00 and the lowest CLRB stock price forecast at $10.00.

The Wall Street analyst predicted that Cellectar Biosciences's share price could reach $10.00 by Mar 10, 2027. The average Cellectar Biosciences stock price prediction forecasts a potential upside of 290.78% from the current CLRB share price of $2.56.

What is CLRB's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: CLRB) Cellectar Biosciences's current Earnings Per Share (EPS) is -$8.35. On average, analysts forecast that CLRB's EPS will be -$3.75 for 2026, with the lowest EPS forecast at -$5.30, and the highest EPS forecast at -$2.90. On average, analysts forecast that CLRB's EPS will be -$3.14 for 2027, with the lowest EPS forecast at -$5.19, and the highest EPS forecast at -$1.59. In 2028, CLRB's EPS is forecast to hit -$0.93 (min: -$1.40, max: -$0.60).

What is CLRB's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: CLRB) forecast ROE is 69.57%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.